Clinical study on the effect of Wenyang Lishui Prescription on drainage volume and upper limb function of breast cancer patients after operation

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037381

Enrollment

Unknown

Registered

2020-08-28

Start date

2021-01-01

Completion date

Unknown

Last updated

2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

experimental group:herb

control group:conventional therapy

Eligibility

Sex/Gender

Male

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Female, >= 18 years old, = 4.0 x 10^9/L, neutrophilic granulocyte count (ANC) >= 1.5 x 10^9/L, and platelet count (PLT) >= 100 x 10^9/L; Hemoglobin (Hb) >= 90g/L;AST(sGOT) and ALT(sGPT) <= 1.5 times the upper limit of normal value, creatinine <= 1.5 times the upper limit of normal value, and total bilirubin <= 1.5 times the upper limit of normal value. 6) No serious damage to heart, liver or kidney function; 7) Agree to participate in clinical trial observation and cooperate with regular visitors; 8) Sign and date the written informed consent.

Exclusion criteria

Exclusion criteria: 1) Women breast-feeding during pregnancy and after pregnancy (blood -HCG excluded); 2) Confirmed women with distant metastasis of breast cancer; 3) Patients with evidence of sensory or motor neurological diseases; 4) Having a clear cardiovascular disease, severe coexisting disease or active infection, including known HIV infection; 5) Have other tumor history; 6) A history of immune diseases; 7) Unable to cooperate with the research for any reason, such as the following: language understanding, unable to go to the research center; 8) Other conditions or diseases that, in the opinion of the investigator, may bring obvious risks to the patient or confuse the results of the study and should be excluded.

Design outcomes

Primary

Measure	Time frame
immune factor;volume of drainage;Scale scores (BWAT scale and DASH scale);	—

Secondary

Measure	Time frame
Adverse reactions;Drug combination;	—

Countries

China

Contacts

Public ContactXinyue Zhang

Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Shanghai University of Traditional Chinese Medicine

947283832@qq.com+86 13127531089

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026